Cabaletta Bio Inc. has released a corporate presentation detailing the progress of its RESET clinical program, which is advancing targeted cellular therapies for autoimmune diseases. The company highlighted that the registrational cohort for myositis within the RESET-Myositis trial will begin in the fourth quarter of 2025, with enrollment already complete in phase 1/2 trials for systemic lupus erythematosus $(SLE)$, lupus nephritis (LN), systemic sclerosis (SSc), and myasthenia gravis $(MG)$. The presentation notes that the FDA has aligned with the single-arm design for the dermatomyositis/antisynthetase syndrome cohort, with a primary endpoint focused on TIS response at 16 weeks. Cabaletta Bio also outlined anticipated milestones across its portfolio, including planned regulatory submissions and commercial supply readiness. The RESET program encompasses six trials targeting a range of autoimmune indications, with disease-specific cohorts designed to transition directly into registrational studies. You can access the full presentation through the link below.